Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 2
1962 1
1963 3
1964 1
1965 2
1967 3
1968 1
1970 1
1971 4
1972 1
1973 1
1974 1
1975 1
1978 1
1984 2
1986 1
1990 1
1991 2
1992 2
1993 1
1995 3
1996 1
1997 2
1998 5
1999 5
2000 5
2001 19
2002 9
2003 20
2004 23
2005 28
2006 19
2007 49
2008 55
2009 39
2010 64
2011 64
2012 82
2013 63
2014 81
2015 116
2016 97
2017 113
2018 95
2019 127
2020 128
2021 128
2022 133
2023 145

Text availability

Article attribute

Article type

Publication date

Search Results

1,596 results

Results by year

Filters applied: . Clear all
Page 1
CRISPR-engineered T cells in patients with refractory cancer.
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH. Stadtmauer EA, et al. Among authors: jung iy. Science. 2020 Feb 28;367(6481):eaba7365. doi: 10.1126/science.aba7365. Epub 2020 Feb 6. Science. 2020. PMID: 32029687 Clinical Trial.
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. Narayan V, et al. Among authors: jung iy. Nat Med. 2022 Apr;28(4):724-734. doi: 10.1038/s41591-022-01726-1. Epub 2022 Mar 21. Nat Med. 2022. PMID: 35314843 Free PMC article. Clinical Trial.
Anti-Inflammatory Actions of Soluble Ninjurin-1 Ameliorate Atherosclerosis.
Jeon S, Kim TK, Jeong SJ, Jung IH, Kim N, Lee MN, Sonn SK, Seo S, Jin J, Kweon HY, Kim S, Shim D, Park YM, Lee SH, Kim KW, Cybulsky MI, Shim H, Roh TY, Park WY, Lee HO, Choi JH, Park SH, Oh GT. Jeon S, et al. Among authors: jung ih. Circulation. 2020 Nov 3;142(18):1736-1751. doi: 10.1161/CIRCULATIONAHA.120.046907. Epub 2020 Sep 4. Circulation. 2020. PMID: 32883094
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion.
Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, Davis MM, Xu J, Boesteanu AC, Barber-Rotenberg JS, Plesa G, Lacey SF, Jadlowsky JK, Siegel DL, Hammill DM, Cho-Park PF, Berger SL, Haas NB, Fraietta JA. Jung IY, et al. Sci Transl Med. 2022 Nov 9;14(670):eabn7336. doi: 10.1126/scitranslmed.abn7336. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350986 Free PMC article.
Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T Cell-Intrinsic Dysfunction.
Jung IY, Bartoszek RL, Rech AJ, Collins SM, Ooi SK, Williams EF, Hopkins CR, Narayan V, Haas NB, Frey NV, Hexner EO, Siegel DL, Plesa G, Porter DL, Cantu A, Everett JK, Guedan S, Berger SL, Bushman FD, Herbst F, Fraietta JA. Jung IY, et al. Cancer Discov. 2023 Jul 7;13(7):1636-1655. doi: 10.1158/2159-8290.CD-22-1175. Cancer Discov. 2023. PMID: 37011008
Novel antitumor therapeutic strategy using CD4+ T cell-derived extracellular vesicles.
Shin S, Jung I, Jung D, Kim CS, Kang SM, Ryu S, Choi SJ, Noh S, Jeong J, Lee BY, Park JK, Shin J, Cho H, Heo JI, Jeong Y, Choi SH, Lee SY, Baek MC, Yea K. Shin S, et al. Among authors: jung i. Biomaterials. 2022 Oct;289:121765. doi: 10.1016/j.biomaterials.2022.121765. Epub 2022 Aug 31. Biomaterials. 2022. PMID: 36067566
Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery.
Jung D, Shin S, Kang SM, Jung I, Ryu S, Noh S, Choi SJ, Jeong J, Lee BY, Kim KS, Kim CS, Yoon JH, Lee CH, Bucher F, Kim YN, Im SH, Song BJ, Yea K, Baek MC. Jung D, et al. Among authors: jung i. J Extracell Vesicles. 2022 Dec;11(12):e12287. doi: 10.1002/jev2.12287. J Extracell Vesicles. 2022. PMID: 36447429 Free PMC article.
1,596 results